肌细胞增强因子2C在胃癌患者中的表达及其临床意义

Expression and clinical significance of myocyte enhancer factor 2C in patients with gastric cancer

目的探讨肌细胞增强因子2C(MEF2C)蛋白在胃癌中的表达情况,并研究与病理和预后的关系。方法使用生物信息学的方法,在TCGA数据库中分析MEF2C在胃癌患者中的表达量及与总生存的关系。选取66例胃癌患者为研究对象,通过对术后胃癌组织标本的免疫组织化学染色,分析MEF2C在胃癌中的表达,结合病理信息和术后随访信息,研究MEF2C对胃癌进展的影响。结果MEF2C在胃癌组织中的高表达与肿瘤大小和肿瘤复发相关(均P<0.05),而与肿瘤分级及淋巴结转移无关(均P>0.05)。结论MEF2C蛋白的高表达可作为胃癌预后不良的标志物。

Objective To investigate the expression of myocyte enhancement factor 2C(MEF2C)protein in gastric cancer,and to study its relationship with pathology and prognosis.Methods Using bioinformatics methods,the expression of MEF2C in gastric cancer patients and its relationship with overall survival were analyzed in the TCGA database.Sixty-six patients with gastric cancer were selected as the research object.The expression of MEF2C in gastric cancer was analyzed by immunohistochemical staining of postoperative gastric cancer tissue samples.By analyzing the expression of MEF2C in gastric cancer,combined with pathological information and postoperative follow-up information,the effect of MEF2C on the progression of gastric cancer was studied.Results The high expression of MEF2C in gastric cancer tissue was related to tumor size and tumor recurrence(all P<0.05),but not related to tumor grade and lymph node metastasis(all P>0.05).Conclusions The high expression of MEF2C protein can be used as a predictor for poor prognosis of gastric cancer.